文献速递甲状腺核医学

68Ga-Trivehexin PET/CT:一种有前景的原发性甲状旁腺功能亢进症新型示踪剂

68Ga-Trivehexin PET/CT: a promising novel tracer for primary hyperparathyroidism.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-07-19

本研究纳入13例原发性甲状旁腺功能亢进症(PHPT)患者,比较68Ga-Trivehexin PET/CT与[99mTc]Tc-MIBI显像-SPECT/CT(MIBI扫描)检出功能亢进甲状旁腺组织的效能。病灶分析中68Ga-Trivehexin检出16个病灶、检出率94.1%,MIBI扫描检出10个、检出率58.8%。作者认为这是68Ga-Trivehexin PET/CT可有效识别功能亢进甲状旁腺组织的首个证据,检出率高,需进一步研究。

要点

  • 患者分析中MIBI扫描检出10例、68Ga-Trivehexin PET/CT检出11例甲状旁腺病灶。
  • 68Ga-Trivehexin PET/CT额外检出7个MIBI扫描阴性的甲状旁腺病灶。
  • 病灶分析中68Ga-Trivehexin检出16个病灶(检出率94.1%),MIBI扫描检出10个(58.8%)。

核心结论

  • 本研究提供首个证据表明68Ga-Trivehexin PET/CT可有效识别功能亢进的甲状旁腺组织,检出率高,需进一步研究以全面探索其在PHPT管理中的潜力。

研究设计与样本

  • 队列纳入13例经生化分析(血清钙、磷及甲状旁腺激素水平)诊断为PHPT的患者。
  • 每例受试者均接受颈部超声、MIBI扫描和68Ga-Trivehexin PET/CT显像。
  • 7例患者补充行4D-CT和[18F]氟胆碱PET/CT。
  • 7例患者的10个病灶接受PTH洗脱(WO)操作。
  • 68Ga-Trivehexin PET/CT结果与其他模态及PTH-WO结果进行比较。

主要发现

  • 10例为散发性PHPT,3例诊断为MEN-1综合征相关PHPT。
  • 1例患者在所有显像模态中均未发现可识别的甲状旁腺病灶。
  • 患者分析中MIBI扫描和68Ga-Trivehexin PET/CT分别检出10例和11例甲状旁腺病灶。
  • 68Ga-Trivehexin PET/CT检出7个MIBI扫描阴性的额外甲状旁腺病灶。
  • 经显像、PTH-WO或两者结合确认17个病灶为功能亢进甲状旁腺组织。

关键数值与推荐

  • 患者分析:MIBI扫描检出10例 vs 68Ga-Trivehexin PET/CT检出11例。
  • 病灶分析:68Ga-Trivehexin检出16个病灶(检出率94.1%)vs MIBI扫描检出10个(检出率58.8%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步研究以全面探索68Ga-Trivehexin PET/CT在PHPT管理中的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study aims to assess 68Ga-Trivehexin PET/CT for detecting hyperfunctioning parathyroid tissue in comparison to [99mTc]Tc-MIBI scintigraphy-SPECT/CT (MIBI scan) in patients with primary hyperparathyroidism (PHPT). METHODS: The cohort comprised 13 patients diagnosed with PHPT based on biochemical analyses, including serum calcium, phosphorus, and parathyroid hormone (PTH) levels. Each participant underwent cervical ultrasonography, MIBI scan, and 68Ga-Trivehexin PET/CT imaging. Complementary 4D-CT and [18F]fluorocholine PET/CT were conducted in 7 patients. Ten lesions of 7 patients underwent PTH wash-out (WO) procedure. 68Ga-Trivehexin PET/CT findings were compared with other modalities and PTH-WO results. RESULTS: Ten patients had sporadic PHPT, while 3 were diagnosed with MEN-1 syndrome-associated PHPT. One patient did not have any identifiable parathyroid lesion across the imaging modalities. On a patient-based analysis, MIBI scan and 68Ga-Trivehexin PET/CT identified parathyroid lesions in 10 and 11 patients, respectively. However, 68Ga-Trivehexin PET/CT detected 7 additional parathyroid lesions that were negative on the MIBI scan. Consequently, 17 lesions were identified and confirmed as hyperfunctioning parathyroid tissue through imaging, PTH-WO, or a combination of both modalities. In lesion-based evaluation, 68Ga-Trivehexin identified 16 lesions compared to 10 by MIBI scan, resulting in a detection rate of 94.1% and 58.8%, respectively. Notably, in three patients who underwent [18F]fluorocholine PET/CT, no lesions were detected; yet 68Ga-Trivehexin PET/CT successfully identified parathyroid lesions in two of these patients. CONCLUSION: Our study provides the first evidence that 68Ga-Trivehexin PET/CT can effectively identify hyperfunctioning parathyroid tissue with a high detection rate warranting further investigations to comprehensively explore its potential in PHPT management.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kuyumcu S, Denizmen D, Has-Simsek D, et al. 68Ga-Trivehexin PET/CT: a promising novel tracer for primary hyperparathyroidism. Eur J Nucl Med Mol Imaging. 2024. PMID: 39028425. doi:10.1007/s00259-024-06846-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。